Management of cancer pain with neuropathic component using transdermal buprenorphine – three clinical cases report

Marcin Janecki; Artur Pakosz

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

4/2014
vol. 6

Send email

Copy url:

abstract:

Case report

Management of cancer pain with neuropathic component using transdermal buprenorphine – three clinical cases report

Marcin Janecki

,

Artur Pakosz

Medycyna Paliatywna 2014; 6(4): 220–224

Online publish date: 2015/03/27

View full text Get citation

Pain is one of the most dominant symptoms in patients with advanced or disseminated cancer, having negative influence on quality of life. Although opioids are mainstream approach in controlling moderate to severe pain, lots of patients are still suffering. One of the responsible reason may be neuropathic component of the cancer pain. The launch of transdermal buprenorphine in 2001 restored interest in the use of the drug to treat moderate to severe cancer pain and some evidence from human clinical trials support it effectiveness in managing neuropathic pain. In this report three clinical cases of patients suffering from chronic cancer pain with neuropathic component treated with transdermal buprenorphine were presented. In all cases buprenorphine tended to be very effective, with favorable safety profile, especially in the group of elderly patients.

keywords:

Management of cancer pain with neuropathic component using transdermal buprenorphine – three clinical cases report

Marcin Janecki , Artur Pakosz

transdermal buprenorphine, cancer pain, neuropathic pain

Marcin Janecki

,

Artur Pakosz